The pharmaceutical firm in Wrexham which has been manufacturing the AstraZeneca vaccine as a part of the UK’s mass vaccination programme is now scaling again manufacturing.
Wockhardt, positioned on the Wrexham Industrial Property, had a contract with the UK Authorities to provide the vaccine for the rollout through the Covid-19 pandemic.
Nevertheless, the corporate mentioned it should ‘right size’ the enterprise as soon as the contracted vaccine manufacturing schedule completes this month, resulting in various job losses consequently.
The agency wouldn’t disclose what number of jobs could be misplaced on the finish of the rollout.
In a press release a spokesperson mentioned: “Wockhardt is extremely proud to have performed a significant position in mitigating the worldwide affect of COVID-19.
“We scaled up at pace to satisfy the pressing want to produce the vaccine, together with investing and recruiting the place wanted to satisfy this demanding deadline.
“The manufacturing production schedule with the UK Government to finish AstraZeneca COVID-19 vaccines is close to being completed with the wide scale rollout of the vaccine across the UK population.
“This has been an unprecedented period in our sterile injectable history and we have not been operating under normal manufacturing timescales or workforce numbers.
“We therefore have made the difficult decision to now undertake a process to ‘right size’ our business to anticipate and meet the future needs of the organisation without the Vaccine work. As a business we are making every effort to keep the impact as small as possible.
“Wockhardt will continue to operate as normal manufacturing all other product lines including critical medicines into the NHS. We will manufacture to the contracted Vaccine production schedule which is due to be completed in the middle of April 2022.”